DCTH

Business Context and Reporting Period

Company: Delcath Systems, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Business Stage: Development Stage Company
Overview: Delcath is a specialty pharmaceutical and medical device company focused on oncology, specifically the development of the Delcath chemosaturation system for delivering high doses of melphalan directly to the liver. The company has no commercial revenue history and relies on equity financing.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased significantly from $14.2 million in Q1 2010 to $1.8 million in Q1 2011. This improvement was driven primarily by a $5.97 million non-cash gain from the change in fair value of warrant liabilities, which offset a $2.3 million increase in operating costs.
• Operating Expenses: Total costs and expenses increased by approximately 42% year-over-year.
  • General & Administrative (G&A): Increased by $1.6 million (to $4.2 million) due to staffing growth (from 24 to 50 employees) and commercialization preparations.
  • Research & Development (R&D): Increased by approximately $700,000 (to $3.6 million) due to expanded activities, despite a reduction in Phase III trial-related expenses.
• Liquidity: Cash and cash equivalents decreased by $6.3 million during the quarter, primarily due to operating cash burn and capital expenditures for equipment ($1.25 million).
• Warrant Liability: The warrant liability decreased from $18.0 million to $12.0 million, resulting in the aforementioned income recognition.

Outlook, Risks, and Management Commentary

• Regulatory Status:
  • Europe: Received CE Mark approval on April 13, 2011, for the Hepatic CHEMOSAT Delivery System, allowing marketing in the European Economic Area. The company is building inventory and a sales infrastructure in Europe.
  • United States: Received a "Refusal to File" letter from the FDA on February 22, 2011, regarding its New Drug Application (NDA). Management intends to resubmit the NDA by December 31, 2011.
• Capital Resources: Management believes current cash reserves ($39.3 million) are sufficient to fund operations through 2011. However, the company expects to continue incurring significant losses and may need to raise additional capital via equity, debt, or strategic alliances to fully commercialize the product.
• Risks:
  • Dependence on FDA approval for U.S. commercialization.
  • Need for additional financing; failure to raise capital could force abandonment of development.
  • Uncertainty regarding the timing and results of future clinical trials and regulatory approvals.
• Unusual Items: The financial results are heavily influenced by the mark-to-market accounting of warrant liabilities, which created a significant non-cash gain in the current quarter.

Investor Verification Checklist

• FDA Resubmission Timeline: Verify the company's ability to address FDA concerns and resubmit the NDA by the stated December 31, 2011 deadline.
• European Commercialization: Monitor the establishment of the European sales force and initial revenue generation following CE Mark approval.
• Cash Burn Rate: Assess whether the $6.7 million quarterly operating cash burn is sustainable given the $39.3 million cash balance and the need for additional capital post-2011.
• Warrant Liability Volatility: Understand that net income/loss figures are distorted by non-cash warrant liability adjustments and focus on cash flow from operations.
• Partnership Agreements: Review the status of the research and distribution agreement with Chi-Fu Trading Co., Ltd. in Taiwan and potential new partnerships in Asia.